FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387475096> ?p ?o ?g. }

• W4387475096 abstract "Miltefosine is the first and only oral medication to be successfully utilized as an antileishmanial agent. However, the drug is associated with differences in exposure patterns and cure rates among different population groups e.g. ethnicity and age (i.e., children v adults) in clinical trials. In this work, mechanistic population physiologically-based pharmacokinetic (PBPK) models have been developed to study the dose-exposure-response relationship of miltefosine in in silico clinical trials and evaluate the differences in population groups, particularly children and adults.The Simcyp population pharmacokinetics platform was employed to predict miltefosine exposure in plasma and peripheral blood mononuclear cells (PBMCs) in a virtual population under different dosing regimens. The cure rate of a simulation was based on the percentage of number of the individual virtual subjects with AUCd0-28 > 535 µg⋅day/mL in the virtual population.It is shown that both adult and paediatric PBPK models of miltefosine can be developed to predict the PK data of the clinical trials accurately. There was no significant difference in the predicted dose-exposure-response of the miltefosine treatment for different simulated ethnicities under the same dose regime and the dose-selection strategies determined the clinical outcome of the miltefosine treatment. A lower cure rate of the miltefosine treatment in paediatrics was predicted because a lower exposure of miltefosine was simulated in virtual paediatric in comparison with adult virtual populations when they received the same dose of the treatment.The mechanistic PBPK model suggested that the higher fraction of unbound miltefosine in plasma was responsible for a higher probability of failure in paediatrics because of the difference in the distribution of plasma proteins between adults and paediatrics. The developed PBPK models could be used to determine an optimal miltefosine dose regime in future clinical trials." @default.
• W4387475096 created "2023-10-11" @default.
• W4387475096 creator A5024060040 @default.
• W4387475096 creator A5025694711 @default.
• W4387475096 creator A5038769454 @default.
• W4387475096 creator A5070060179 @default.
• W4387475096 creator A5071591643 @default.
• W4387475096 creator A5077563862 @default.
• W4387475096 date "2023-10-10" @default.
• W4387475096 modified "2023-10-12" @default.
• W4387475096 title "Assessing Dose-Exposure–Response Relationships of Miltefosine in Adults and Children using Physiologically-Based Pharmacokinetic Modeling Approach" @default.
• W4387475096 cites W1833793080 @default.
• W4387475096 cites W1981968564 @default.
• W4387475096 cites W1982896728 @default.
• W4387475096 cites W2001536171 @default.
• W4387475096 cites W2016587111 @default.
• W4387475096 cites W2018986030 @default.
• W4387475096 cites W2028165836 @default.
• W4387475096 cites W2031425275 @default.
• W4387475096 cites W2031426306 @default.
• W4387475096 cites W2041065394 @default.
• W4387475096 cites W2041666513 @default.
• W4387475096 cites W2047581463 @default.
• W4387475096 cites W2066680067 @default.
• W4387475096 cites W2069913623 @default.
• W4387475096 cites W2072044044 @default.
• W4387475096 cites W2092896290 @default.
• W4387475096 cites W2096439392 @default.
• W4387475096 cites W2101502132 @default.
• W4387475096 cites W2112439874 @default.
• W4387475096 cites W2113830209 @default.
• W4387475096 cites W2121179442 @default.
• W4387475096 cites W2126420606 @default.
• W4387475096 cites W2133257763 @default.
• W4387475096 cites W2137109737 @default.
• W4387475096 cites W2148707789 @default.
• W4387475096 cites W2165334931 @default.
• W4387475096 cites W2171230483 @default.
• W4387475096 cites W2172300605 @default.
• W4387475096 cites W2297436867 @default.
• W4387475096 cites W2421608912 @default.
• W4387475096 cites W2471625978 @default.
• W4387475096 cites W2519666645 @default.
• W4387475096 cites W2567041620 @default.
• W4387475096 cites W2593007632 @default.
• W4387475096 cites W2742371482 @default.
• W4387475096 cites W2742972753 @default.
• W4387475096 cites W2750822783 @default.
• W4387475096 cites W2783115227 @default.
• W4387475096 cites W2784240093 @default.
• W4387475096 cites W2802689556 @default.
• W4387475096 cites W2890715470 @default.
• W4387475096 cites W2902880491 @default.
• W4387475096 cites W3048539852 @default.
• W4387475096 cites W3090530295 @default.
• W4387475096 cites W3120475004 @default.
• W4387475096 cites W3184223167 @default.
• W4387475096 cites W3209795396 @default.
• W4387475096 cites W3210803166 @default.
• W4387475096 cites W3211644351 @default.
• W4387475096 cites W4220769730 @default.
• W4387475096 cites W4280544609 @default.
• W4387475096 cites W4296773172 @default.
• W4387475096 doi "https://doi.org/10.1007/s11095-023-03610-0" @default.
• W4387475096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37816929" @default.
• W4387475096 hasPublicationYear "2023" @default.
• W4387475096 type Work @default.
• W4387475096 citedByCount "0" @default.
• W4387475096 crossrefType "journal-article" @default.
• W4387475096 hasAuthorship W4387475096A5024060040 @default.
• W4387475096 hasAuthorship W4387475096A5025694711 @default.
• W4387475096 hasAuthorship W4387475096A5038769454 @default.
• W4387475096 hasAuthorship W4387475096A5070060179 @default.
• W4387475096 hasAuthorship W4387475096A5071591643 @default.
• W4387475096 hasAuthorship W4387475096A5077563862 @default.
• W4387475096 hasBestOaLocation W43874750961 @default.
• W4387475096 hasConcept C112705442 @default.
• W4387475096 hasConcept C126322002 @default.
• W4387475096 hasConcept C185867374 @default.
• W4387475096 hasConcept C203014093 @default.
• W4387475096 hasConcept C2776555147 @default.
• W4387475096 hasConcept C2777288759 @default.
• W4387475096 hasConcept C2778689377 @default.
• W4387475096 hasConcept C2781417161 @default.
• W4387475096 hasConcept C2908647359 @default.
• W4387475096 hasConcept C535046627 @default.
• W4387475096 hasConcept C71924100 @default.
• W4387475096 hasConcept C98274493 @default.
• W4387475096 hasConcept C99454951 @default.
• W4387475096 hasConceptScore W4387475096C112705442 @default.
• W4387475096 hasConceptScore W4387475096C126322002 @default.
• W4387475096 hasConceptScore W4387475096C185867374 @default.
• W4387475096 hasConceptScore W4387475096C203014093 @default.
• W4387475096 hasConceptScore W4387475096C2776555147 @default.
• W4387475096 hasConceptScore W4387475096C2777288759 @default.
• W4387475096 hasConceptScore W4387475096C2778689377 @default.
• W4387475096 hasConceptScore W4387475096C2781417161 @default.
• W4387475096 hasConceptScore W4387475096C2908647359 @default.
• W4387475096 hasConceptScore W4387475096C535046627 @default.
• W4387475096 hasConceptScore W4387475096C71924100 @default.

• next